Pain intensity, long‐term · patients with sciatica
1 finding from 1 review
Functional status, short‐term · patients with sciatica
1 finding from 1 review
Functional status, long‐term · patients with sciatica
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Cardiovascular events · people at high risk of or withcardiovascular disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical CVD events (CVD mortality and non‐fatal MI) · people at high risk of or withcardiovascular disease
It is very uncertain whether mindfulness‐based interventions (MBIs) changes clinical CVD events (CVD mortality and non‐fatal MI) compared with non‐active comparators (very low certainty).
1 finding from 1 review
Systolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Diastolic blood pressure (mmHg), change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Anxiety · people at high risk of or withcardiovascular disease
1 finding from 1 review
Depression, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
Perceived stress, change from baseline · people at high risk of or withcardiovascular disease
1 finding from 1 review
General well‐being · people at high risk of or withcardiovascular disease
1 finding from 1 review
Adverse events · people at high risk of or withcardiovascular disease
Mindfulness‐based interventions (MBIs) showed no clear difference in adverse events compared with non‐active comparators (low certainty).
1 finding from 1 review